Form 4: Lisata Therapeutics SVP James Nisco Reports Stock Transactions

James Nisco, SVP, Fin/Treas, Chief Actg Off of Lisata Therapeutics, reports acquisition of restricted stock and stock options, as well as disposals to cover tax liabilities.

Summary

• On January 9, 2025, James Nisco, SVP, Fin/Treas, Chief Actg Off of Lisata Therapeutics, acquired 15,000 shares of common stock as restricted stock awards.
• These awards vest in four equal installments, with the first vesting immediately and subsequent installments vesting annually over the next three years.
• On the same date, Nisco also acquired 7,000 stock options with an exercise price of $3.8, vesting similarly to the restricted stock.
• Nisco disposed of 2,131, 1,137 and 781 shares of common stock on January 9, 2025, and 416 shares on January 10, 2025, to cover tax liabilities related to the vesting of restricted stock.
• The price for the disposals on January 9, 2025 was $3.8 and $3.73 on January 10, 2025.
• Following these transactions, Nisco beneficially owns 23,491 shares of common stock, including 16,624 unvested restricted stock, and 7,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and reflect standard compensation practices. There is no indication of unusual or concerning activity.

Positives

• The acquisition of restricted stock and stock options suggests confidence in the company's future performance.

Negatives

• The disposal of shares to cover tax liabilities, while routine, slightly reduces Nisco's holdings.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities, allowing investors to monitor the actions of company executives and directors.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.

Key Dates